Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2023 Dec 26

PMID 38148417

Authors

Jingjing Zhu

John P H Wilding

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To highlight that body fat depletion (the Yin paradigm) with glucose-lowering treatments (the Yang paradigm) are associated with metabolic benefits for patients with type 2 diabetes mellitus (T2DM).

Recent Findings: The sodium-glucose cotransporter-2 inhibitor-mediated sodium/glucose deprivation can directly improve glycemic control and kidney outcome in patients with T2DM. The glucose deprivation might also promote systemic fatty acid β-oxidation to deplete ectopic/visceral fat and thereby contribute to the prevention of cardiovascular diseases. As with metabolic surgery, bioengineered incretin-based medications with potent anorexigenic and insulinotropic efficacy can significantly reduce blood glucose as well as body weight (especially in the ectopic/visceral fat depots). The latter effects could be a key contributor to their cardiovascular-renal protective effects. In addition to a healthy diet, the newer glucose-lowering medications, with body fat reduction effects, should be prioritized when treating patients with T2DM, especially for those with established cardiovascular/renal risks or diseases.

Citing Articles

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.

Zhu J, Wilding J, Gu X World J Diabetes. 2024; 15(10):2135-2146.

PMID: 39493569 PMC: 11525725. DOI: 10.4239/wjd.v15.i10.2135.

References

Hall J, do Carmo J, da Silva A, Wang Z, Hall M . Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15(6):367-385. PMC: 7278043. DOI: 10.1038/s41581-019-0145-4. View

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R . Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023; 389(10):877-888. DOI: 10.1056/NEJMoa2302392. View

Davies M, Bergenstal R, Bode B, Kushner R, Lewin A, Skjoth T . Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7):687-99. DOI: 10.1001/jama.2015.9676. View

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

Brown E, Heerspink H, Cuthbertson D, Wilding J . SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021; 398(10296):262-276. DOI: 10.1016/S0140-6736(21)00536-5. View

Dragano N, Monfort-Pires M, Velloso L . Mechanisms Mediating the Actions of Fatty Acids in the Hypothalamus. Neuroscience. 2019; 447:15-27. DOI: 10.1016/j.neuroscience.2019.10.012. View

Frayn K . Non-esterified fatty acid metabolism and postprandial lipaemia. Atherosclerosis. 1999; 141 Suppl 1:S41-6. DOI: 10.1016/s0021-9150(98)00216-0. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400(10365):1788-1801. PMC: 7613836. DOI: 10.1016/S0140-6736(22)02074-8. View

10.

Alonso A, Bahnson J, Gaussoin S, Bertoni A, Johnson K, Lewis C . Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial. Am Heart J. 2015; 170(4):770-777.e5. PMC: 4576158. DOI: 10.1016/j.ahj.2015.07.026. View

11.

Maya-Monteiro C, Correa-da-Silva F, Hofmann S, Hesselink M, la Fleur S, Yi C . Lipid Droplets Accumulate in the Hypothalamus of Mice and Humans with and without Metabolic Diseases. Neuroendocrinology. 2020; 111(3):263-272. DOI: 10.1159/000508735. View

12.

Mallick R, Duttaroy A . Modulation of endothelium function by fatty acids. Mol Cell Biochem. 2021; 477(1):15-38. PMC: 8755678. DOI: 10.1007/s11010-021-04260-9. View

13.

Gastaldelli A, Cusi K, Lando L, Bray R, Brouwers B, Rodriguez A . Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022; 10(6):393-406. DOI: 10.1016/S2213-8587(22)00070-5. View

14.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

15.

Dar S, Siddiqi A, Alabduladhem T, Rashid A, Sarfraz S, Maniya T . Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. Ann Med Surg (Lond). 2022; 77:103633. PMC: 9142616. DOI: 10.1016/j.amsu.2022.103633. View

16.

Scott R, Bloom S . Problem or solution: The strange story of glucagon. Peptides. 2018; 100:36-41. PMC: 5805853. DOI: 10.1016/j.peptides.2017.11.013. View

17.

Yang W, Zhan M, Li Z, Sun X, Zhang K . Major Adverse Cardiovascular Events Among Obese Patients with Diabetes After Metabolic and Bariatric Surgery: a Meta-analysis of Matched Cohort and Prospective Controlled Studies with 122,361 Participates. Obes Surg. 2023; 33(7):2098-2107. DOI: 10.1007/s11695-023-06634-y. View

18.

Patel K, Bahnson J, Gaussoin S, Johnson K, Pi-Sunyer X, White U . Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial. Circulation. 2020; 142(25):2420-2430. PMC: 8366747. DOI: 10.1161/CIRCULATIONAHA.120.050941. View

19.

Saxena A, Frias J, Brown L, Gorman D, Vasas S, Tsamandouras N . Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(5):e2314493. PMC: 10203889. DOI: 10.1001/jamanetworkopen.2023.14493. View

20.

Nauck M, Mirna A, Quast D . Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic.... Diabetes Obes Metab. 2023; 25(5):1361-1371. DOI: 10.1111/dom.14988. View